“These findings are an exciting example of the promise of drug repurposing, using existing medicines in new and unexpected ways,” said Gelfand, of UVA’s Center for Advanced Vision Science. “Ultimately ...

Prozac could offer the first treatment for the leading cause of blindness among people over 50, new research from the UVA School of Medicine suggests. UVA’s Bradley D. Gelfand, PhD, and collaborators ...

Increased risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies. Advise families and caregivers of the need for close observation and communication ...

A medication meant to lift spirits may be falling flat. New research suggests that an antidepressant commonly prescribed to children and teens may not be as effective as once thought. Now, some ...

Neuroscientists recently identified molecular mechanisms in the brain that may explain why the active ingredient (fluoxetine) in selective serotonin reuptake inhibitors (SSRIs) sold under brand names ...

“These findings are an exciting example of the promise of drug repurposing, using existing medicines in new and unexpected ways,” said researcher Bradley D. Gelfand, PhD, of UVA’s Center for Advanced ...

Evidence shows weak antiviral activity and no improvement in symptom outcomes. Study: Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive ...

An antidepressant best known as Prozac could offer the first treatment for the leading cause of blindness among people over 50, new research suggests. An antidepressant best known as Prozac could ...

An antidepressant best known as Prozac could offer the first treatment for the leading cause of blindness among people over 50, new research from the University of Virginia School of Medicine suggests ...